Evaluation of the Immunogenicity and Efficacy of HIV-1 Clade A BG505 SOSIP.664 Env Glycoprotein Trimer Vaccine Administered with TLR Agonist or Alum Adjuvants

有效的艾滋病毒疫苗和其他预防策略的开发依赖于在临床前研究中使用非人类灵长类动物(NHP)。为了满足这一需求，西蒙疫苗评价股(SVEU)提供国家惠普资源，主要支持艾滋病疫苗和预防模式的临床前评价。SVEU计划将为NIAID提供使用NHP模型评估候选艾滋病疫苗的能力，在NHP模型中，可以对系统和粘膜免疫反应进行彻底评估，可以轻松地测试疫苗效力，可以确定降低病毒感染风险的相关性，并可以采取方法来提高临床疫苗的免疫原性和有效性。SVEU将提供反应灵敏、灵活的疫苗资源，供NIH支持的研究人员使用，并可以支持艾滋病疫苗研究的所有阶段，从候选艾滋病疫苗的临床前评估或临床测试，目的是确定一种将产生能够预防或控制病毒感染的免疫反应的疫苗。SVEU的范围包括卫生保健计划的住房和维护，开展支持艾滋病预防研究的研究，重点是艾滋病疫苗，支持国家卫生计划繁殖群体，以及这些活动的一般行政和管理。

The development of effective HIV vaccines and other prevention strategies relies on the use of nonhuman primates (NHPs) in preclinical studies. To meet this need, the Simian Vaccine Evaluation Units (SVEUs) provide NHP resources that primarily support preclinical evaluation of AIDS vaccines and prevention modalities. The SVEU program will provide NIAID the ability to evaluate candidate AIDS vaccines using NHP models in which thorough evaluations of systemic and mucosal immune responses can be conducted, vaccine efficacy can easily be tested, correlates of reduced risk of virus acquisition can be identified, and approaches to enhance immunogenicity and efficacy of clinical vaccines can be conducted. The SVEUs will provide a responsive, flexible vaccine resource that is available to NIH-supported researchers and can support all stages of AIDS vaccine research, from preclinical evaluation or clinical testing of candidate AIDS vaccines, with the objective of identifying a vaccine that will generate immune responses able to prevent or control viral infection. The scope of the SVEUs includes housing and maintenance of NHPs, the conduct of studies supporting AIDS prevention research, with an emphasis on AIDS vaccines, support of a NHP breeding colony, and general administration and management of these activities.